This morning, the Marinus Pharmaceuticals (NASDAQ:MRNS) stock is expected to be on the radars of investors owing to the 37% gain recorded this past Friday. The rally was triggered owing to a new announcement from the company on the same day.
The Announcement
The company announced on Friday that the TrustTSX Phase III trial into its ganaxolone product for the treatment of seizures in adults and children brought about by TSC (tuberous sclerosis complex). Marinus Pharmaceuticals announced that the product failed to hit its primary endpoint in the trial.
The Phase III global placebo-controlled and double-blind trial included 129 patients in total. The data revealed that the median reduction of frequency of seizures had been brought down by 19.7% by the product in comparison to placebo. However, the reduction was not deemed to have been statistically significant.
Safety Profile
In the news release, Marinus Pharmaceuticals announced that the product demonstrated a safety profile that remained consistent with clinical studies. It was deemed generally well tolerated by the patients.
The aim of the trial had been to show a statistically significant change in frequency of seizures in a span of 28 days. However, it fell short of that goal. That being said, the news did not dampen the spirits of investors, who seemed to continue to be bullish on the Marinus Pharmaceuticals stock.
CEO Quote
Marinus chairman and CEO Scott Braunstein said: “As the first controlled trial in TSC that allowed enrollment of patients taking a range of concomitant antiseizure medications, which included mTOR inhibitors and cannabidiol, these data represent a significant advancement in our understanding of the use of ganaxolone with other standard of care treatments.
| +/- EMA(20) | 1.48 (-72.63%) |
| +/- SMA(50) | 1.53 (-73.52%) |
| +/- SMA(200) | 3.98 (-89.82%) |
| 5-Day Perf. | -78.1% |
| 1-Month Perf. | -76.72% |
| 3-Month Perf. | -71.37% |
| 6-Month Perf. | -71.47% |
| YTD Perf. | -96.27% |
| 1-Year Perf. | -93.81% |
| RSI(14) | 22.57 |
| ATR(14) | 0.21 |
| ADX(14) | 34.64 |
| Beta (5Y) | 1.64 |
 stock surges 37%: What’s the Buzz?){kind=link}